Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Rizo-Topete Lilia Maria

Rizo-Topete Lilia Maria

University of Nuevo Leon, Mexico

Title: Experience in CRRT using PRISMA monitor in the ICU of a university hospital in Northeast mexico

Biography

Biography: Rizo-Topete Lilia Maria

Abstract

The AKI appears in 5-25% of patients in ICU, of which 6% will require RRT. If the AKI is associated with MODS mortality will be 50% and if RRT is required this will be 80%. Sepsis and Acute tubular perfussion are causes of AKI. The CRRT is an option for hemodynamically unstable patients and those whom can not handle the volume or metabolic disorders. The hemodialysis (HD) in critical patients is a common practice, however, the use of continous therapy with hemodiafiltration modality requires a special characteristics. Objective: Describe the experience using PRISMA monitor in our center. Material and Methods: Retrospective, descriptive, observational study,All patients who were given CRRT with PRISMA our center from March 2013 to November 2014. Data analysis was performed using Excel and SPSS programs. There is no conflict of interest and was conducted according to the ethics committee of our hospital. Results: CRRT was applied in an active way to 18 patients, 15 males (83%) and 3 females (17%), the average age was 43.9 years (Min. 17 Max. 78). 14 presented AKIN III, 4 where known with CKD. The most common cause of AKI was septic shock (83.3%). The oliguric AKI was the most common form of presentation in 86% of the patients. The average days of stay on ICU 17.5 days (SD 16.5). The average days of arrival and development of AKI is 2.6 days (SD 2.9). APACHE II and SOFA admission average was 30.5 (SD 6.5) and 13.6 (of 3.9) respectively. It was possible to stop CRRT in 5 of 18 patients (27.7 %), 2 patients continued with HD. There was a patient with combined therapy PRISMA-MARS. Only 3 out of 18 patients (20%) survived the hospital stay. In the comparative analysis of the groups: survivors versus non survivors there were non statistically significant differences in the SOFA and APACHE II scores or in the days of stay in the ICU with a IC of 95%. As for the prescription, blood flow measured in ml/min, extraction measured in ml/hr, the dialysate, the reinjection and total UF, showed no statistically significant differences with a IC of 95%. Discussion and Conclusions: According to the results, our experience is similar to that reported in the literature with high mortality in patients with AKI and MODS, despite improvement in renal function. With the methodology used and the present number of patients, it´s not possible to point out a good or bad prediction factor on the clinical characteristics of the patients or the therapeutic prescription.